Giuseppe Banna: Key considerations for implementing the LAURA study findings into clinical practice
Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post on LinkedIn about his new letter published in NEJM.
“Excited to share our letter on the LAURA study published in the NEJM Group!
We discussed key considerations for implementing the LAURA study findings into clinical practice, such as the impact of initial PET staging and the need for sufficient tissue availability during screening.
While the study underscores the progression-free survival benefits of osimertinib in stage III EGFR-mutated NSCLC, there’s still much to explore for optimized clinical application.
Looking forward to more advancements and discussions in Lung Cancer and Oncology!”
“Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC”
Authors: Giuseppe Luigi Banna and Alfredo Addeo.
More posts featuring Giuseppe Banna.
Giuseppe Banna is a Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust and the Candiolo Cancer Institute IRCCS. He leads the Translational Research and Clinical Trials Unit for Thoracic Tumors.
Additionally, he serves as an Honorary Teacher Practitioner at the Universities of Nottingham and Lincoln, and is affiliated with United Lincolnshire Hospitals NHS Trust.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023